Building on FHIR for Pharmaceutical Research
FHIR (pronounced "fire") is a new, free of cost, platform that has the ability to access and create data though EHR systems. Wayne Kubick writes that using such a platform could truly re-engineer how pharma collects data during clinical trials.
Recently I participated in a “Partners in Interoperability” workshop in Washington DC. The meeting brought together senior decision makers from the clinician, payer and biopharmaceutical communities to exchange ideas on how to make more progress toward a mutual, worthy goal of “an interoperable healthcare system that leads to better patient care and improved outcomes.” The focus of the meeting was on how to achieve this goal through the use of FHIR® -
FHIR (pronounced “fire”) is a new standards-based framework and platform that makes it possible to tap directly into Electronic Healthcare Record (EHR) systems to retrieve and even create protected healthcare and administrative data. It is based on a small set of ~100 core information resources, modular bundles of healthcare information, which can be tied to different databases and can be easily deployed for multiple purposes. In the USA, FHIR has attracted great interest from the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025